11β-Hydroxysteroid dehydrogenase type 1 inhibition protects against the development of adverse metabolic and bone effects of prednisolone: A randomized, double-blind, placebo-controlled trial

MLA

Jeremy Tomlinson, et al. “11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Protects against the Development of Adverse Metabolic and Bone Effects of Prednisolone: A Randomized, Double-Blind, Placebo-Controlled Trial.” Endocrine Abstracts, Aug. 2020. EBSCOhost, https://doi.org/10.1530/endoabs.70.oc3.6.

APA

Jeremy Tomlinson, Rury R. Holman, Paul Stewart, Olorunsola F. Agbaje, Anastasia Arvaniti, Riccardo Pofi, Joanne E. Milton, Andrew Whittaker, Nantia Othonos, & Ruth L. Coleman. (2020). 11β-Hydroxysteroid dehydrogenase type 1 inhibition protects against the development of adverse metabolic and bone effects of prednisolone: A randomized, double-blind, placebo-controlled trial. Endocrine Abstracts. https://doi.org/10.1530/endoabs.70.oc3.6

Chicago

Jeremy Tomlinson, Rury R. Holman, Paul Stewart, Olorunsola F. Agbaje, Anastasia Arvaniti, Riccardo Pofi, Joanne E. Milton, Andrew Whittaker, Nantia Othonos, and Ruth L. Coleman. 2020. “11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Protects against the Development of Adverse Metabolic and Bone Effects of Prednisolone: A Randomized, Double-Blind, Placebo-Controlled Trial.” Endocrine Abstracts, August. doi:10.1530/endoabs.70.oc3.6.